In a fiery Senate hearing, Senator Jeff Merkley grilled Health and Human Services Secretary Robert F. Kennedy Jr. over ๐ถ๐๐๐๐๐ถ๐๐พ๐ธ๐๐ that President Trump is shielding Monsanto from lawsuits linked to its cancer-causing pesticide Roundup, citing Kennedy’s own past criticisms and recent White House meetings that could undermine public health protections.
The confrontation erupted as Merkley pressed Kennedy on a stark reversal in federal reports about glyphosate, the key ingredient in Monsanto’s Roundup herbicide, which has been linked to cancer in numerous studies. Just months earlier, in May 2025, Kennedy’s department had highlighted glyphosate’s dangers, but by September, it vanished from discussions amid reported White House engagements with Bayer executivesโthe company that owns Monsanto. Merkley’s pointed questions ๐ฎ๐๐น๐ธ๐ผ๐ฎ๐ญ potential influence peddling at the highest levels, raising alarms about corporate sway over government decisions.
Kennedy, once a vocal critic of Monsanto, faced tough scrutiny on whether he knew about these meetings. He denied awareness initially, but the exchange grew heated when Merkley referenced a looming Supreme Court case where Monsanto seeks immunity from lawsuits by cancer victims. Trump’s administration filed a brief supporting Monsanto, a move that thrilled the company and contradicted Kennedy’s history of fighting them.
In 2018, Kennedy helped secure a $290 million verdict for a groundskeeper who developed cancer from Roundup use, declaring Monsanto’s actions as reckless. Yet, now, as part of Trump’s cabinet, his silence on the issue has drawn fire. Merkley demanded to know if Kennedy opposed Trump’s stance, and Kennedy admitted he had, but only privately, fueling accusations of inaction.
The tension peaked when Merkley invoked Kennedy’s own words from 2020, where he compared Monsanto to a โLex Luthorโ villain and revealed Trump’s message to Monsanto leaders: โWe have got your back.โ This revelation underscored a perceived betrayal, as Kennedy, once an environmental crusader, now appears entangled in administration policies favoring big agriculture over public safety.
Experts warn that glyphosate’s widespread use affects millions, contaminating food supplies and posing risks to farmers and consumers alike. With 80% of American farms reliant on the chemical, any regulatory shift could disrupt agriculture, but at what cost to human health? Kennedy argued for balancing these concerns, claiming sudden bans could cripple food production, but Merkley dismissed this as deflection.
The hearing highlighted deeper rifts within the administration, as Kennedy insisted he had voiced disagreements internally, though evidence of public pushback remains scarce. Critics, including environmental groups, are calling for transparency, fearing that corporate interests are prioritizing profits over lives, especially with the Supreme Court case set for next Monday.
This isn’t just about one pesticide; it’s a broader battle for accountability in an era where industry lobbying can silence science. Merkley’s relentless questioning painted a picture of a government at war with itself, where former advocates like Kennedy might be compromised by political loyalties.
As the exchange unfolded, Kennedy grew defensive, accusing Merkley of grandstanding, but the senator fired back, emphasizing his duty to protect Americans from toxic exposures. The back-and-forth revealed a administration divided, with Kennedy labeling the critique as overblown, yet failing to quell growing suspicions.
Public health advocates are rallying, pointing to decades of evidence linking glyphosate to non-Hodgkin lymphoma and other cancers, as seen in cases like that of Dewayne Johnson, Kennedy’s former client. If the Supreme Court sides with Monsanto, it could shield the company from thousands of pending lawsuits, potentially endangering millions more.
The urgency of this moment cannot be overstated. With Trump’s brief to the Court advocating for Monsanto, and Kennedy’s tepid response, the stakes for environmental justice are sky-high. Families affected by Roundup-related illnesses are watching closely, hoping for real action rather than rhetoric.
In the hearing room, the atmosphere was electric, with Merkley’s pointed barbs cutting through Kennedy’s explanations. This clash isn’t isolated; it’s symptomatic of a larger struggle between corporate power and public welfare in Washington.
Kennedy’s evolution from anti-Monsanto warrior to cabinet member has raised eyebrows, especially given his past statements decrying the company’s influence. Now, as the administration pushes to protect glyphosate-dependent farming, questions about conflicts of interest loom large.
Merkley didn’t hold back, accusing Kennedy of being โkryptoniteโ within the administrationโtoxic and enabling harm. Such vivid language underscored the personal and professional betrayal at play, making this more than policy debate; it’s a moral reckoning.
The implications extend beyond this hearing. If unchecked, this could erode trust in health agencies, allowing dangerous chemicals to persist in everyday products. Consumers deserve better, and this confrontation might be the catalyst for change.
Kennedy maintained that national security and food supply concerns justify caution, but Merkley countered that health must come first. The exchange ended without resolution, leaving the public demanding answers and accountability.
As details emerge, the pressure on the White House intensifies. With the Supreme Court case imminent, every day counts in this fight against corporate impunity. This breaking story is a wake-up call for all Americans to demand transparency and prioritize health over profits.
The broader context reveals a pattern of industry influence in Trump-era policies, from environmental rollbacks to health exemptions. Kennedy’s role in this saga adds a layer of irony, given his legacy as an environmental icon.
Yet, for now, the focus remains on this tense hearing, where words clashed like weapons in a battle for truth. Senator Merkley’s stand could inspire a wave of scrutiny, forcing the administration to confront the human cost of its decisions.
In the end, this isn’t just about Monsanto or Roundup; it’s about whether government serves the people or powerful interests. The world is watching as this ๐น๐๐ถ๐๐ถ unfolds, with potential ripple effects on global health standards and corporate accountability.